03:35:52 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-30 Kvartalsrapport 2024-Q2
2024-04-12 X-dag ordinarie utdelning TRMED 0.00 NOK
2024-04-11 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-08-31 Kvartalsrapport 2023-Q2
2023-04-27 X-dag ordinarie utdelning TRMED 0.00 NOK
2023-04-26 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-08-31 Kvartalsrapport 2022-Q2
2022-04-29 X-dag ordinarie utdelning TRMED 0.00 NOK
2022-04-28 Årsstämma 2022
2022-03-01 Bokslutskommuniké 2021
2021-11-18 15-10 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-04-28 Årsstämma 2021
2021-04-16 X-dag ordinarie utdelning TRMED 0.00 NOK
2021-03-22 Extra Bolagsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-10-21 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-06-11 X-dag ordinarie utdelning TRMED 0.00 NOK
2020-06-10 Årsstämma 2020
2020-05-26 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-23 Kvartalsrapport 2019-Q1
2019-04-26 X-dag ordinarie utdelning TRMED 0.00 NOK
2019-04-25 Årsstämma 2019
2019-02-18 Extra Bolagsstämma 2019
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-31 X-dag ordinarie utdelning TRMED 0.00 NOK
2018-05-30 Kvartalsrapport 2018-Q1
2018-05-30 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-12-20 Extra Bolagsstämma 2017
2017-11-22 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-26 X-dag ordinarie utdelning TRMED 0.00 NOK
2017-05-24 Kvartalsrapport 2017-Q1
2017-05-24 Årsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2016-11-23 Kvartalsrapport 2016-Q3
2016-10-12 Extra Bolagsstämma 2016
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-31 Kapitalmarknadsdag 2016
2016-05-20 X-dag ordinarie utdelning TRMED 0.00 NOK
2016-05-19 Årsstämma 2016
2016-05-19 Kvartalsrapport 2016-Q1
2016-02-26 Bokslutskommuniké 2015
2015-11-17 Kapitalmarknadsdag 2015
2015-10-21 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-27 Kvartalsrapport 2015-Q1
2015-03-09 Årsstämma 2015
2014-11-12 Extra Bolagsstämma 2014

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Thor Medical är ett läkemedelsbolag. Bolaget specialiserar sig inom utveckling av antikroppsläkemedel för behandling utav hematologisk cancer. Störst specialisering återfinns inom precisionsterapi som används i den kliniska fasen. Övriga sjukdomar som behandlas är non-hodgkins lymfom (NHL). Bolaget grundades under 2009 och har sitt huvudkontor i Oslo, Norge.
2022-12-09 18:31:54

Oslo, Norway, 9 December 2022

Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") today announces an update following the Extraordinary General Meeting held on 1 December at which the proposed merger transaction with APIM Therapeutics AS ("APIM") did not obtain a sufficient majority of votes and was therefore voted down.

A new Extraordinary General Meeting ("EGM") will be convened by the Board of Directors with an agenda proposed by North Energy. North Energy is currently the largest shareholder of Nordic Nanovector.

The current Board of Directors of Nordic Nanovector has decided to resign at the upcoming EGM and not to stand for re-election at that meeting.

An invitation to this new EGM to elect both members of the Nomination Committee and a new Board of Directors will be sent out at the start of next week.

Hans Peter Bøhn, as the only remaining member of the Nomination Committee, may be contacted to propose new members of the Nomination Committee and new members of the Board of Directors.

The Board and the company continue to further preserve cash resources and as a result, Malene Brondberg, current interim Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") will transition out of the Company. A search for a new CEO is expected to commence immediately after a new Board of Directors of Nordic Nanovector has been elected.  

Chairman, Jan H. Egberts commented: "While the Board believed that the proposed merger with APIM was in the best interests of all shareholders, we did not receive the required level of shareholder support for this transaction. Following this result, Malene Brondberg will end her role as interim CEO and CFO and the current Board will not stand for re-election. I would like to extend the Board's thanks to Malene for her support of the Company, particularly during the recent and very difficult circumstances we have faced following the disappointing results from the PARADIGME study for Betalutin® in third-line Follicular Lymphoma".

Contacts

Malene Brondberg, Interim CEO and CFO of Nordic Nanovector

+ 44 7561 431 762

ir@nordicnanovector.com

International Media: Frazer Hall / Mark Swallow (MEDiSTRAVA Consulting)

+44 203 928 6900

nordicnanovector@medistrava.com

Media in Norway - Jan Lilleby / Stein Jacob Frisch (Lilleby Frisch)

+47 916 10 911

sjf@lillebyfrisch.no

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company's pipeline includes:
  • Betalutin® and Humalutin®, both CD37-targeting radioimmunotherapies incorporating the beta emitter lutetium-177 to treat non-Hodgkin's lymphoma (NHL);
  • Alpha37, a CD37-targeting radioimmunotherapy candidate incorporating the alpha-emitting radionuclide lead-212, currently being explored with partner Oranomed for chronic lymphocytic leukaemia;
  • Multiple fully humanized anti-CD37 antibodies with potential in haematological cancers and autoimmune diseases; and
  • A CD37 DOTA CAR-T cell opportunity in haematological cancers, which is being advanced via a research collaboration with the University of Pennsylvania.

Further information can be found at www.nordicnanovector.com.